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Abstract
Objectives: Measurement of treatment satisfaction in diabetes is important as it has been shown to be associated
with positive outcomes, reduced disease cost and better health. The aim of this study was to assess the construct
validity and internal consistency reliability of the Greek version of the Diabetes Treatment Satisfaction
Questionnaire (DTSQ).
Methods: A sample of type II diabetes patients (N = 172) completed the DTSQ status version, the SF-36 health
survey and also provided data regarding treatment method, clinical and socio-demographic status. Instrument
structure, reliability (Cronbach’s a) and construct validity (convergent, discriminative, concurrent and known-groups)
were assessed.
Results: The DTSQ measurement properties were confirmed in the Greek version with confirmatory factor analysis
(CFA). Scale reliability was high (Cronbach’s a = 0.92). Item-scale internal consistency and discriminant validity were
also good, exceeding the designated success criteria. Significant correlations were observed between DTSQ items/
overall score and SF-36 scales/component scores, which were hypothesized to measure similar dimensions. Known
groups’ comparisons yielded consistent support of the construct validity of the instrument.
Conclusions: The instrument was well-accepted by the patients and its psychometric properties were similar to
those reported in validation studies of other language versions. Further research, incorporating a longitudinal study
design, is required for examining test-retest reliability and responsiveness of the instrument, which were not
addressed in this study. Overall, the present results confirm that the DTSQ status version is a reasonable choice for
measuring diabetes treatment satisfaction in Greece.
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Background
Diabetes is a major cause of morbidity and mortality
and the prevalence of the disease has reached epidemic
proportions, with the global number of people with dia-
betes projected to rise from approximately 170 million
in 2000 to approximately 370 million in 2030 [1]. About
90-95% of all cases are type 2, also known as adult-
onset diabetes [2]. Diabetes is further burdened with an
increased risk of complications, which have important
effects on patients’ quality of life as well as socio-eco-
nomic implications [3]. Overall, diabetes affects various
domains of functioning and well-being and people with
diabetes generally report worse health status and other
outcomes than those without [4-6]. Severe dietary
restriction, self administration of medications, routine
blood glucose monitoring, and exercise demands are
some of the ways in which diabetes can impact on qual-
ity of life.
Treatment satisfaction is defined by the individual’s
view of treatment and outcomes [7] and is particularly
important for the acceptance of, and compliance with,
treatment regimens [8]. Numerous health organizations
have included measurement of patient satisfaction in
projects designed to impro v eq u a l i t yo fc a r e[ 9 , 1 0 ] ,
which is evaluated by three equally important measures:
structure, process and outcomes. Treatment satisfaction
i si n c l u d e di nt h ep r o c e s sc o m p o n e n ta n di su s e da sa n
important indicator of quality of care [10]. In diabetes,
it has been shown that increased treatment satisfaction
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disease cost [12-14], and improved health status
[11,15,16].
The Diabetes Treatment Satisfaction Questionnaire
(DTSQ) [17,18] is a globally accepted and used instru-
ment to evaluate treatment satisfaction in diabetes mel-
litus. It has been recommended by the World Health
Organisation and the International Diabetes Federation
as useful in assessing outcomes of diabetes care [19] and
has been used in many previous studies [11,15,20].
Given its widespread acceptance as a valid measure of
treatment satisfaction in diabetes, the purpose of this
study was to evaluate the psychometric properties of the
original (status) version of the Greek DTSQ.
Methods
Instruments
The DTSQ was designed to make an assessment of total
diabetes treatment satisfaction, treatment satisfaction in
specific areas and perceived frequencies of hyperglyce-
mia and hypoglycemia. It consists of eight items rated
on a 0-6 scale. Six items specifically address: satisfaction
with current treatment (item 1), treatment convenience
(item 4), flexibility of treatment (item 5), understanding
of diabetes (item 6), recommending treatment (item 7)
and continuing treatment (item 8). The scores are
summed into an overall satisfaction index ranging from
0 (very dissatisfied) to 36 (very satisfied). Items 2 and 3
evaluate the perceived frequency of hyper- and hypogly-
cemia respectively, with the scale reversed and lower
scores indicating reduced hyper or hypoglycaemia. The
DTSQ has been used extensively in clinical trials and in
routine clinical monitoring and has now been linguisti-
cally validated in more than 100 languages. It has been
used to measure patient satisfaction with treatment and
h a sp r o v e dt ob eh i g h l ys e n s i t i v et oc h a n g e si nt r e a t -
ment, e.g. from rigid to flexible insulin treatment [21],
from tablets to insulin injections [22] and from one
insulin regimen to another [23,24]. The Greek version
of the DTSQ has been linguistically validated using stan-
dard and well recognised methods [25], and the instru-
ment developers were actively involved from the back
translations onward, commenting and discussing at each
stage.
The SF-36 Health Survey includes eight dimensions:
physical functioning, “role physical”, bodily pain, general
health, vitality, social functioning, “role emotional” and
mental health [26]. Each dimension is scored on a 0-100
scale with 0 and 100 corresponding to worst and best
health status respectively [27], and the eight dimensions
can also be summarized in two summary scores of phy-
sical and mental health [28]. The instrument has been
translated into Greek and its reliability and validity were
established in a representative sample of adults living in
the greater Athens area. It was found to have high inter-
nal consistency reliability, convergent and discriminative
validity and able to distinguish between groups of
respondents in the expected manner (known-groups’
validity) on the basis of gender, age and socio-economic
status [29]. Using the same sample, the eight-scale
structure of the Greek version of the instrument has
been confirmed as well [30]. The SF-36 has been shown
to discriminate well between perceptions of people with
or without one or more chronic diseases [31], and has
been previously used in Greek studies of people with
diabetes [32,33].
Sample and data collection
The data were collected between November 2008 and
February 2009. The sample consisted of type 2 diabetes
patients living in areas served by the “Agia Varvara”
Health Centre, located close to Heraklion on the island
of Crete. Consecutive patients were approached by the
same social worker and asked to participate in the
study. It should be noted that most of the residents in
this Health Centre’s catchment area are older people
and of relatively low educational status. The presence of
the social worker, with whom the patients were familiar
with, aimed to assist them in understanding the ques-
tions and to resolve any misconceptions. The survey
included the SF-36 and DTSQ as well as socio-demo-
graphic and other diabetes-specific questions. Comple-
tion time was approximately 25 minutes and 172 out of
191 patients visiting the facility during the study period
agreed to participate (90.1% response rate). The Health
Centre’s Review Board granted ethical approval for this
study and all participants provided informed consent.
Analysis
Descriptive statistics and response frequencies for each
item were calculated in order to examine central ten-
dency, variability and symmetry. Scale reliability was cal-
culated using Cronbach’s alpha and the 0.70 standard
for group-level comparisons was adopted [34]. Confir-
matory factor analysis (CFA) was used to confirm that
the measurement properties of the original version of
the instrument apply to the Greek version as well.
Goodness of fit was examined via: i) c
2/df (chi-square/
degrees freedom) with values of less than 3 indicating a
good fit, ii) root mean square error of approximation
(RMSEA) with values < 0.05 indicating a close fit and
iii) comparative fit index (CFI) for which values > 0.9
indicate a good fit [35].
Item internal consistency, which is substantial when
correlation between an item and its hypothesised scale
(corrected for overlap) is > 0.40, and item discriminant
validity which is successful when correlation between an
item and its own scale is significantly higher (> 2
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to examine the hypothesised structure of the instru-
ment. Correlations between DTSQ items and SF-36
scales were examined to assess convergent construct
validity, based on substantial correlations of related
items/scales reported in the literature. Specifically, posi-
tive correlations were expected between treatment satis-
faction and domains of physical and mental health
status [37,38]. Known groups’ validity was assessed by
testing the DTSQ’s ability to discriminate between
groups of patients known to differ. Gender, age, years
with diabetes, BMI, HbA1c level, treatment method,
comorbidities, macro- and microvascular complications
were used as testing criteria, and differences were exam-
ined with t-test and ANOVA. According to the litera-
ture, lower treatment satisfaction was expected in
females [15,38,39], in younger diabetics [11], in insulin-
treated patients [15,38,40], in the presence of diabetic
complications [11,15,38,40], and in patients with higher
BMI [41] and HbA1c [11,17] values. Multivariate OLS
regression identified independent sociodemographic,
clinical and treatment-related variables associated with
treatment satisfaction and perceived hyper- and hypo-
glycaemia. Probabilities < 0.05 were regarded as statisti-
cally significant. All analyses were performed using SPSS
software, version 17.0 (SPSS Inc., Chicago IL).
Results
The demographic, treatment and clinical characteristics
of the participants are presented in Table 1. The mean
age of the entire sample was 65.2 years and the majority
was women. The mean duration of diabetes was 5.2
years and the dominant treatment method was oral
hypoglycaemic agents (OHA). The most common
comorbid conditions in this sample were hyperlipidae-
mia and hypertension, whereas a high portion of respon-
dents also had arthropathy. The most prevalent diabetic
complication was macrovascular heart disease. At least
one microvascular complication (retinopathy, neuropa-
thy or nephropathy) was present in 7.6% of the sample.
Diabetic foot, present in 6.4% of the patients, was exam-
ined separately as it could be argued that it has some
elements of both micro- and macrovascular damage.
Descriptive statistics for the eight DTSQ items are
presented in Table 2. Response rates were very high
throughout, providing evidence that items and response
choices were clear and unambiguous. Furthermore,
most response choices were used in all of the items.
The mode, i.e. the most frequently occurring response,
was 3 for all but one of the six satisfaction items. Mean
and median satisfaction values were in close proximity
(17.5 and 18.0 respectively) implying a fairly symmetrical
distribution of responses around the mean value. Item 1
regarding satisfaction with current treatment and item 7
regarding recommending the current form of treatment
to someone with the same kind of diabetes had the
highest and lowest mean scores respectively, which is
surprising as these two concepts -yet distinct- are
related to each other. Ceiling effects were not serious,
suggesting that the instrument could record improve-
ments at follow-up.
T h eC F As h o w e dac o v a r i a n c eo f0 . 3 9b e t w e e nt h e
two factors implying good discriminative validity. Factor
loadings ranged between 0.67-0.87 for treatment satis-
faction and 0.48-1.22 for diabetes management (Table
3). Goodness of fit indices were: c
2/df = 2.01, RMSEA =
0.08 and CFI = 0.97, which imply satisfactory or better
model fit [42]. Internal consistency of the 6-item scale
(excluding items 2 and 3) was high (a = 0.92) and no
item appeared problematic as overall internal consis-
tency did not increase after deleting any of the items.
Item internal consistency was substantial as the correla-
tions between items and the overall DTSQ score was
strong (with the respective item excluded each time)
and ranged between 0.70 and 0.81, thus clearly exceed-
ing the > 0.40 limit. Item discriminant validity was suc-
cessful as the correlations between each item and
overall DTSQ were significantly higher by two standard
errors or more than with items 2 and 3, thus confirming
the hypothesised DTSQ structure.
Evidence of convergent construct validity (Table 4)
was obtained by examining correlations between DTSQ
items and SF-36 scales which were assumed to be con-
ceptually related based on findings from the literature.
Table 1 Sample characteristics (N = 172)
(Mean ± SD)
Age (mean ± SD) 65.2 ± 13.1
Diabetes duration (mean ± SD) 5.2 ± 4.9
BMI (Kg/m
2) (mean ± SD) 31.2 ± 5.9
N (%)
Gender (female) 107 (62.2)
Recent HbA1c level
< 6.5% 49 (28.5)
6.5-7.5% 74 (43.0)
> 7.5% 49 (28.5)
Diabetes control method
Oral agents 137 (79.7)
Insulin 35 (21.3)
Comorbid conditions
Hyperlipidaemia 95 (55.2)
Hypertension 79 (45.2)
Arthropathy 31 (18.0)
COPD 15 (8.7)
Macrovascular heart disease 63 (36.6)
Microvascular disease 13 (7.6)
Diabetic foot 11 (6.4)
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tions were found between the DTSQ score and SF-36
physical functioning, general health, vitality, social func-
tioning and mental health scales, as well as with the
physical and mental health component scores. As for
the specific DTSQ items, satisfaction with current treat-
ment (item 1), treatment understanding (item 6), treat-
ment recommendation (item 7) and continuing
treatment (item 8), were the most strongly associated
with the SF-36 scales. All the above-mentioned correla-
tions were moderate or better and Pearson’s r typically
exceeded 0.3. On the other hand, perceived frequency of
hyperglycaemic episodes was inversely associated with
the general health, social functioning, role emotional
and mental health dimensions, and with the mental
health component. Perceived hypoglycaemia was nega-
tively (and significantly) linked to general health and
social functioning.
Univariate analyses revealed no correlation between
gender and treatment satisfaction (Table 5). As for age,
lower mean DTSQ scores were observed with increasing
age although the differences showed only a trend to
significance (P = 0.067). On the other hand, the associa-
tion between treatment/clinical parameters and satisfac-
tion was stronger as expected. Specifically, DTSQ scores
were significantly lower (P <0 . 0 0 1 )i ng r o u p sw i t h
higher HbA1c values (> 7.5%) and in patients taking
insulin. Presence of macrovascular coronary disease was
significantly related with lower treatment satisfaction (P
< 0.05) and patients with foot ulcers were also less satis-
fied. Patients with at least one microvascular complica-
tion such as retinopathy, neuropathy or nephropathy or
one comorbid condition such as hyperlipidaemia, hyper-
tension, arthropathy or COPD had slightly lower DTSQ
scores, however differences were not significant. Per-
ceived frequencies of hyper- and hypoglycaemia showed
similar relationships with HbA1c and treatment method
as the overall satisfaction score. The same applied for
macrovascular coronary disease. The most noteworthy
difference was the pronounced gender effect as women
reported less hyper- and hypoglycaemia than men (P <
0.05 and P < 0.01 respectively).
The significance of the above-mentioned relationships
between treatment satisfaction and disease management
Table 2 DTSQ item descriptive statistics
Item Description Mean (SD) Median Item response distribution (%)
0 12345 6
Treatment Satisfaction
1 Current treatment 3.17 (1.03) 3.00 1.2 4.1 18.0 39.0 29.1 8.7 -
4 Treatment convenience 3.00 (1.00) 3.00 0.6 5.2 22.7 43.6 21.5 5.8 0.6
5 Treatment flexibility 2.93 (1.09) 3.00 2.3 5.8 25.0 36.6 23.8 6.4 -
6 Treatment understanding 3.03 (1.07) 3.00 - 7.0 23.8 38.4 20.3 10.5 -
7 Treatment recommendation 2.23 (1.20) 2.00 7.6 19.8 31.4 29.1 8.1 4.1 -
8 Treatment continuation 3.00 (1.09) 3.00 1.2 3.5 26.2 37.8 26.2 5.2 -
DTSQ score 17.48 (5.54) 18.00
Diabetes Management
2 Perceived hyperglycaemia 2.58 (1.48) 2.00 6.4 20.3 25.0 18.6 16.3 13.4 -
3 Perceived hypoglycaemia 3.53 (1.37) 4.00 1.7 8.1 14.5 18.0 26.7 30.2 0.6
Table 3 Factor loadings, internal consistency and item-scale correlations (N = 172)
Item Description Factor loadings
(CFA)
Internal consistency reliability
1 Item-scale correlations
2
Overall Item deleted DTSQ score Item 2 Item 3
1 Current treatment 0.77 0.92 0.90 0.76 -0.17* -0.26***
4 Treatment convenience 0.83 0.90 0.78 -0.18* -0.35***
5 Treatment flexibility 0.74 0.90 0.73 -0.18* -0.32***
6 Treatment understanding 0.87 0.89 0.80 -0.08 -0.25***
7 Treatment recommendation 0.67 0.91 0.70 -0.01 -0.31***
8 Treatment continuation 0.87 0.89 0.81 -0.24** -0.38***
2 Perceived hyperglycaemia 0.48 0.78 NA -0.20* - 0.64***
3 Perceived hypoglycaemia 1.22 NA -0.38* 0.64*** -
1 Cronbach’s alpha
2 Corrected for overlap
*P < 0.05, **P < 0.01, ***P < 0.001 according to Pearson’s correlation
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6). In the case of overall DTSQ scores, age, higher
HbA1c values, treatment with insulin and diabetic foot
were identified as significant predictors of reduced satis-
faction, with the model explaining an overall 28.5% of
the variance. The two clinical variables, i.e. HbA1c
values and insulin treatment w e r et h eo n l ys i g n i f i c a n t
predictors of increased perceived hyper- and hypogly-
caemia, with the regression models explaining 23.2%
and 26.8% of the variance respectively.
Discussion
The DTSQ status version has been linguistically validated
into Greek according to procedures documented else-
where [25]. The aim of this study was to collect evidence
of the validity and reliability of this Greek version for use
in studies with Greek samples. The expected added value
to the existing international body of knowledge on the
subject is the increased confidence in results from
national studies employing the instrument and the poten-
tial for international comparisons. Although generic
health status instruments (e.g. SF-36) have shown their
validity in Greek samples of people with diabetes [32,33],
and the DTSQ has been used in one previous Greek
study [43], we are unaware of previous studies measuring
the psychometric properties of any diabetes treatment
satisfaction instrument in Greece, implying that this
research can fill an existing void in this area.
T h eo v e r a l lr e s u l t sf o rt h ep s y c h o m e t r i cp r o p e r t i e so f
the instrument were good. The absence of ceiling
effects, although a sign of good discriminative ability, is
fairly surprising in the context of measurement of satis-
faction, which is known to often lead to skewed distri-
butions of responses. In this respect, our results are
inconsistent with previous studies having suggested
maximum or close-to-maximum DTSQ scores at base-
line. One explanation for the relatively low satisfaction
reported here (17.5 mean DTSQ score) may come from
the poor health status of the sample, although it is
impossible to support any casual relationships with the
data. The SF-36 scale scores (not shown) were lower for
physical functioning, general health, vitality (P <0 . 0 0 1 ) ,
mental health (P < 0.01), social functioning and pain (P
< 0.05) than the respective general population scores
reported in the instrument validation study [29]. There
is strong evidence in the literature supporting the posi-
tive association between health status and diabetes treat-
ment satisfaction [11,15].
A cultural effect, in this particular sample, might also
exist and explain to some extent the absence of ceiling
effects. The health care facility in this study is located in
a semi-urban/rural area where patients are attended by
a generalist and not a diabetic specialist. Although the
literature shows similar satisfaction between diabetes
patients of family practitioners and endocrinologists/
internists [44], studies in Greece have shown higher
satisfaction with health services in urban compared to
rural health facilities [45]. Furthermore, our low satisfac-
tion scores are probably not linked to the presence of
the social worker during completion of the survey by
the patients, as this would have been expected to gener-
ate higher scores due to the possibility of social desir-
ability bias. In any case, ceiling effects provide little
opportunity for registering improvement in satisfaction
with treatment or strategy being assessed [46,47], and it
was for this reason that the DTSQ change version was
designed and developed, and proposed for use in inter-
vention studies in addition to the DTSQ (status) [48].
The measurement properties of the instrument were
confirmed with CFA and goodness of fit was demon-
strated via three different indices for which values were
within, or close to, the suggested limits. Scale internal
consistency reliability was very high and exceeded the
corresponding reliability coefficients reported in similar
Table 4 Pearson’s correlations between DTSQ and SF-36 scales and summary components (N = 172)
DTSQ items and scale
1 SF-36 scales SF-36 components
PF RP BP GH VT SF RE MH PCS MCS
Current treatment (item 1) 0.31*** 0.29*** 0.24*** 0.46*** 0.30*** 0.33*** 2.83*** 0.29*** 0.36*** 0.32***
Perceived hyperglycaemia (item 2) -0.17* -0.12 0.01 -0.20** -0.08 -0.21** -0.16* -0.19* -0.09 -0.21**
Perceived hypoglycaemia (item 3) -0.12 -0.11 -0.02 -0.18* -0.07 -0.18* -0.08 -0.07 -0.10 -0.10
Treatment convenience (item 4) 0.16* 0.12 0.11 0.36*** 0.17* 0.19* 0.09 0.17* 0.20** 0.17*
Treatment flexibility (item 5) 0.14 0.09 0.06 0.34*** 0.13 0.17* 0.15* 0.19* 0.14 0.21**
Treatment understanding (item 6) 0.30*** 0.22** 0.21** 0.47*** 0.32*** 0.32*** 0.18* 0.29*** 0.33*** 0.30***
Treatment recommendation (item 7) 0.27*** 0.16* 0.17* 0.35*** 0.26*** 0.29*** 0.12 0.24** 0.27*** 0.24**
Treatment continuation (item 8) 0.28*** 0.19* 0.18* 0.45*** 0.31*** 0.30*** 0.14 0.29*** 0.30*** 0.29***
Overall score (treatment satisfaction) 0.28*** 0.19* 0.20** 0.47*** 0.27*** 0.32*** 0.17* 0.28*** 0.31*** 0.28***
1 DTSQ overall satisfaction score is the sum of responses to items 1, 4, 5, 6, 7 and 8
*P < 0.05, **P < 0.01, *** P < 0.001
Abbreviations: PF - Physical Function, RP - Role Physical, BP - Bodily Pain, GH - General Health, VT - Vitality, SF - Social Functioning, RE - Role Emotional, MH -
Mental Health, PCS - Physical Component Score, MCS - Mental Component Score
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minant validity were good as well, providing evidence to
confirm the hypothesised structure of the DTSQ and to
suggest that the translation of the items and the
response choices are appropriate. It should be noted
that the cross-sectional design employed in the present
study precluded the assessment of responsiveness of the
instrument.
In diabetes, the measurement of health status is con-
comitant with assessments of satisfaction with the qual-
ity of care [37]. In the present study, significant
correlations were observed between the DTSQ items
and overall satisfaction and the SF-36 scales and compo-
nent scores. This was expected since diabetes is a
chronic disease with a wide range of associated disability
and discomfort which is typically captured by health
Table 5 Perceived treatment satisfaction, hyper- and hypoglycaemia by demographic and diabetes-related variables
Variable N (%) Overall Treatment
Satisfaction
Perceived
Hyperglycemia
Perceived
Hypoglycemia
Mean P-value Mean P-value Mean P-value
Overall 172 (100) 17.48 - 2.58 - 3.53 -
Gender
Male 65 (37.8) 16.86 0.258 2.94 0.013 3.91 0.005
Female 107 (62.2) 17.85 2.36 3.30
Age group
< 55 33 (19.2) 19.42 0.067 2.67 0.985 3.64 0.908
55-64 38 (22.1) 17.95 2.58 3.47
65-74 59 (34.3) 17.02 2.54 3.58
≥ 75 42 (24.4) 16.17 2.57 3.43
Years with diabetes
1-3 86 (50.0) 18.00 0.273 2.38 0.214 3.42 0.504
4-9 55 (32.0) 17.42 2.78 3.58
≥ 10 31 (18.0) 16.13 2.77 3.74
BMI
18.5-24.9 16 (9.3) 17.69 0.918 2.25 0.232 3.44 0.578
25.0-29.9 70 (40.7) 17.47 2.84 3.66
30.0-34.9 47 (27.3) 17.06 2.34 3.57
≥ 35.0 39 (22.7) 17.48 2.54 3.28
HbA1c
< 6.5% (good) 49 (28.5) 20.43 < 0.001 1.53 < 0.001 2.41 < 0.001
6.5%-7.5% (fair) 74 (43.0) 17.31 2.82 3.86
> 7.5% (poor) 49 (28.5) 14.78 3.27 4.14
Control method
Oral agents 138 (80.2) 18.61 < 0.001 2.34 < 0.001 3.30 < 0.001
Insulin
1 34 (19.8) 12.88 3.56 4.47
≥ 1 comorbidity
2
Yes 135 (79.7) 17.16 0.147 2.58 0.951 3.54 0.833
No 37 (20.3) 18.65 2.59 3.49
Coronary/vascular disease
Yes 63 (36.6) 16.07 0.012 2.92 0.021 3.71 0.180
No 109 (63.4) 18.08 2.39 3.42
≥ 1 microvascular complication
3
Yes 13 (7.6) 17.15 0.828 2.62 0.931 3.23 0.417
No 159 (92.4) 17.50 2.58 3.55
Diabetic foot
Yes 11 (6.4) 12.55 0.002 3.27 0.108 3.73 0.622
No 161 (93.6) 17.81 2.53 3.52
1 Approximately half the diabetics in this group take oral agents alongside insulin
2 Including hyperlipidaemia, hypertension, arthropathy or COPD
3 Including retinopathy, neuropathy or nephropathy
P-values derived from independent samples t-test or ANOVA
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which shows that poorer treatment satisfaction is gener-
ally associated with worse perception of physical and
mental well-being [15,41,49]. In one particular study
employing the DTSQ and the SF-12 (a shorter version
of the SF-36 for measuring health status), lower treat-
ment satisfaction was correlated with worse self-rated
mental and physical health status scores [38]. However,
in another DTSQ validation study employing the SF-36,
strong correlations were found between WHO-WBQ
scales and the mental dimensions of the SF-36 question-
naire, but not between DTSQ and SF-36 scores, suggest-
ing that additional data are required to determine the
most appropriate health status instrument to be admi-
nistered alongside the DTSQ [51]. Regarding the two
perceived blood glucose control items, the correlations
between perceived hyper- and hypoglycaemia and SF-36
were in accordance with results from a similar DTSQ
validation study [41].
Known-groups’ validity was supported by the presence
of macrovascular complications (coronary and/or vascu-
lar disease) negatively affecting treatment satisfaction.
The same applied for diabetic foot, and although the
subsample with foot ulcers was quite small (N = 11),
the DTSQ decrements were sufficiently large to provide
statistical power for comparisons. These findings are
consistent with the results of numerous previous studies
having reported a negative effect of the presence of any
diabetic complications [11,15,38,41,52]. Higher satisfac-
tion was recorded from patients on oral agents, as
opposed to insulin therapy. Apart from the obvious fact
that injecting insulin is less comfortable than taking a
Table 6 Multivariate OLS regression models
DTSQ Predictors Β SE t P-sig R
2
Satisfaction (Constant) 30.976 2.686 11.532 < 0.001 0.285
Gender (Female) 0.011 0.765 0.015 0.988
Age
1 -1.031 0.406 -2.540 0.012
Years therapy
1 -0.399 0.514 -0.777 0.438
BMI class
1 0.019 0.416 0.045 0.964
HbA1c
1 -1.874 0.511 -3.668 < 0.001
Control method
1 -4.586 0.997 -4.601 < 0.001
Comorbidity -1.002 0.897 -1.117 0.266
Coronary/vascular disease -0.340 0.840 -0.405 0.686
Microvascular disease 2.398 1.444 1.661 0.099
Diabetic foot -3.190 1.558 -2.047 0.042
Perceived Hyperglycaemia (Constant) 0.944 0.740 1.275 0.204 0.232
Gender (Female) -0.254 0.211 -1.205 0.230
Age
1 -0.121 0.112 -1.082 0.281
Years therapy
1 0.198 0.142 1.397 0.164
BMI class
1 -0.099 0.115 -0.864 0.389
HbA1c
1 0.676 0.141 4.800 < 0.001
Control method
1 0.709 0.275 2.583 0.011
Comorbidity -0.047 0.247 -0.189 0.851
Coronary/vascular disease 0.384 0.231 1.660 0.099
Microvascular disease -0.303 0.398 -0.762 0.447
Diabetic foot 0.233 0.429 0.544 0.587
Perceived Hypoglycaemia (Constant) 1.815 0.674 2.694 0.008 0.268
Gender (Female) -0.281 0.192 -1.463 0.145
Age
1 -0.077 0.102 -0.757 0.450
Years therapy
1 0.202 0.129 1.569 0.119
BMI class
1 -0.115 0.104 -1.105 0.271
HbA1c
1 0.698 0.128 5.444 < 0.001
Control method
1 0.768 0.250 3.073 0.002
Comorbidity 0.043 0.225 0.190 0.850
Coronary/vascular disease 0.148 0.211 0.704 0.482
Microvascular disease -0.646 0.362 -1.784 0.076
Diabetic foot -0.265 0.391 -0.677 0.499
1 According to the groups designated in Table 5
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Page 7 of 10pill, this particular result might be indicating that
patients perceive insulin treatment as deterioration in
their health status. It might also be that diabetic patients
who need insulin have longer disease duration with
more complications. Higher HbA1c levels were also
linked to lower treatment satisfaction in the univariate
analyses and were also significant predictors of satisfac-
tion, hyper- and hypoglycaemia in the respective regres-
sion models. In any case, there is disagreement in the
literature on the association of these parameters and
satisfaction as some studies have demonstrated the exis-
tence of such a relationship [11,15,37], while others
have not [49,50].
Gender, disease duration and obesity were apparently
not related to treatment satisfaction, however the former
was associated with perceived hyper- and hypoglycae-
mia, as men experienced episodes more frequently than
women. Most studies have indicated lower satisfaction
among women [15,49,51], although others could not
find any gender effects [41,53]. Age was a borderline sig-
nificant (P < 0.067) factor with a negative relationship
with satisfaction, however it was a significant predictor
in the regression model, in accordance with results
reported elsewhere [41]. The role of obesity in treatment
satisfaction is not clear and some studies have con-
firmed it as a disadvantage [11,51], whereas other have
not [49,53]. In our study, obesity was a non-relevant fac-
tor for treatment satisfaction. It is worth mentioning
that the mean BMI in the sample was 31.2 Kgr/m
2,
which is apparently high but not unusual in this type of
population, as shown in a relevant Greek study [32].
Moreover, the prevalence of obesity in Greece is the
highest among European countries, reaching 26.0% and
18.2% in men and women respectively [54]. Finally, no
association between comorbidities and treatment satis-
faction was found, despite the high prevalence of
comorbidities in this sample. A possible explanation is
that the most common comorbid conditions were
hyperlipidaemia and hypertension, which are “silent”
diseases.
A potential limitation of this study might arise from
the DTSQ being completed in the presence of a social
worker who the patients knew and felt comfortable
with. This approach, as opposed to self-administration
for which the instrument was designed, was adopted as
it would otherwise be difficult for this aged and low
educational status rural sample to successfully complete
the survey. One might claim that this may have wea-
kened the results on quality of completion, since the
social worker could actively ask for responses, or even
have led patients to be more sincere, as patients tend to
give socially desirable responses so as not to criticize
their treatment (or their physician) [55,56]. As pre-
viously mentioned, the absence of a ceiling effect and
the low satisfaction scores recorded in this study imply
that social desirability bias was not a problem.
Conclusions
Internal consistency reliability and cross-sectional con-
struct validity of the Greek DTSQ were satisfactorily
demonstrated; however the cross-sectional design of the
present study precludes examining test-retest reliability
and responsiveness. Thus, a longitudinal study design
could be considered to overcome these limitations, as
well as to validate the present results. The instrument
was well-accepted by the patients and its psychometric
properties were similar to those reported in validation
studies of other language versions. Overall, the results
confirm that the DTSQ status version is a reasonable
choice for measuring diabetes treatment satisfaction in
Greece. Providing that future research addresses the
aforementioned issues, as well as testing the DTSQ
change version, results from Greek studies can be
expected to add to the international body of knowledge
on treatment satisfaction.
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